Status
Conditions
Treatments
About
This study will evaluate the safety and efficacy of Jianfei Kangfu Cao in the treatment of primary Sjogren's syndrome associated interstitial lung disease.
Full description
This study will be a randomized, double-blind, positive control clinical trial with a course of 24 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
138 participants in 2 patient groups
Loading...
Central trial contact
Jianchun Mao, Master; Zhujing Zhu, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal